] . (2012). Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant, 18(7), 1007-11. presented at the 2012 Jul. doi:10.1016/j.bbmt.2012.04.014
. (2014). Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and M. Biol Blood Marrow Transplant, 20(10), 1566-72. presented at the 2014 Oct. doi:10.1016/j.bbmt.2014.06.010
. (2014). Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood, 124(22), 3221-7; quiz 3335. presented at the 2014 Nov 20. doi:10.1182/blood-2014-06-577023
. (2014). Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood, 124(8), 1372-7. presented at the 2014 Aug 21. doi:10.1182/blood-2014-04-567164